3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
GIST
1
Interventions
Imatinib Mesylate
28
nilotinib
21
Cytarabine
8
Cyclophosphamide
8
Methotrexate
7
Peripheral Blood Stem Cell Transplantation
6
Interferon-alpha
6
Hydroxyurea
6
bosutinib
5
asciminib
5
Whole-Body Irradiation
5
Mycophenolic Acid
5
Tacrolimus
4
Dasatinib
4
Busulfan
4
peginterferon alfa-2a
3
fludarabine phosphate
3
fludarabine
3
Radiotherapy
3
Cyclosporine
3
sargramostim
2
ponatinib
2
Sirolimus
2
Idarubicin
2
Etoposide
2
BID protein, human
2
thymoglobulin
1
peginterferon alfa-2b
1
pegaspargase
1
olverembatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
olverembatinib
×
Clear all
NCT06423911
2025-06-03
POLARIS-2
Ascentage Pharma Group Inc.
Phase 3
Recruiting
285 enrolled